{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:35:26Z","timestamp":1770813326024,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T00:00:00Z","timestamp":1458691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.03.073","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T01:08:21Z","timestamp":1459300101000},"page":"2953-2958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Status of research and development of vaccines for Streptococcus pyogenes"],"prefix":"10.1016","volume":"34","author":[{"given":"Andrew C.","family":"Steer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Guilherme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole J.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Schodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre R.","family":"Smeesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.073_bib0305","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of Group A Streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of Group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2016.03.073_bib0315","first-page":"1","article-title":"Saving mothers\u2019 lives: reviewing maternal deaths to make motherhood safer: 2006\u20132008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom","volume":"118","author":"Cantwell","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0320","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0325","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5694\/j.1326-5377.2001.tb143394.x","article-title":"Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease later in life","volume":"174","author":"White","year":"2001","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0330","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S1473-3099(15)00132-2","article-title":"Prevalence of scabies and impetigo worldwide: a systematic review","volume":"15","author":"Romani","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2261-5-11","article-title":"Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis","volume":"31","author":"Robertson","year":"2005","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0340","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCULATIONAHA.108.836510","article-title":"Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa","volume":"120","author":"Karthikeyan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0345","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1161\/CIR.0b013e3181dbdde0","article-title":"Letter by Carapetis regarding article. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa?","volume":"121","author":"Carapetis","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0350","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/QCO.0b013e3283511d27","article-title":"Streptococcal skin infection and rheumatic heart disease","volume":"25","author":"Parks","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0355","first-page":"CD002227","article-title":"Penicillin for secondary prevention of rheumatic fever","author":"Manyemba","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2016.03.073_bib0360","first-page":"e4033","article-title":"Rheumatic heart disease-attributable mortality at ages 5\u201369 years in Fiji: a five-year, national, population-based record-linkage cohort study","volume":"15","author":"Parks","year":"2015","journal-title":"PLoS Neglect Trop Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrcardio.2013.34","article-title":"Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease","volume":"10","author":"Remenyi","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-0484","article-title":"Burden and economic cost of Group A Streptococcal pharyngitis","volume":"121","author":"Pfoh","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0375","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehu449","article-title":"Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)","volume":"36","author":"Zuhlke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0380","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.110.2.271","article-title":"Persistence of type-specific antibodies in man following infection with Group A Streptococci","volume":"110","author":"Lancefield","year":"1959","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.89.3.307","article-title":"Current knowledge of the type specific M antigens of Group A Streptococci","volume":"89","author":"Lancefield","year":"1962","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0390","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/QCO.0b013e328332bbfe","article-title":"Group A Streptococcal vaccines: facts versus fantasy","volume":"22","author":"Steer","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0395","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1172\/JCI107372","article-title":"Protective study with a Group A Streptococcal M protein vaccine. Infectivity challenge of human volunteers","volume":"52","author":"Fox","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/131.3.217","article-title":"Protective studies with a Group A Streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract","volume":"131","author":"Polly","year":"1975","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0405","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/infdis\/138.6.712","article-title":"Protective studies with Group A Streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with type 3 or type 12 Group A Streptococcus","volume":"138","author":"D\u2019Alessandri","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0410","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of Group A Streptococci: systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0415","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jiu260","article-title":"A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development","volume":"210","author":"Sanderson-Smith","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0420","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.vaccine.2013.01.019","article-title":"Potential coverage of a multivalent M protein-based Group A Streptococcal vaccine","volume":"31","author":"Dale","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0425","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(04)00975-2","article-title":"Acute rheumatic fever: a chink in the chain that links the heart to the throat","volume":"4","author":"McDonald","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0430","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0b013e318281da11","article-title":"Progress toward a global Group A Streptococcal vaccine","volume":"32","author":"Steer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.03.073_bib0435","doi-asserted-by":"crossref","first-page":"B216","DOI":"10.1016\/j.vaccine.2012.09.045","article-title":"Group A Streptococcal vaccines: paving a path for accelerated development","volume":"31","author":"Dale","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0440","doi-asserted-by":"crossref","first-page":"167089","DOI":"10.1155\/2015\/167089","article-title":"Correlates of protection for M protein-based vaccines against Group A Streptococcus","volume":"2015","author":"Tsoi","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0445","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","article-title":"Rheumatic fever following streptococcal vaccination. Report of three cases","volume":"207","author":"Massell","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0450","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1016\/j.vaccine.2010.05.018","article-title":"Protective efficacy of Group A Streptococcal vaccines containing type-specific and conserved M protein epitopes","volume":"28","author":"Penfound","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0455","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/521264","article-title":"The epidemiology of invasive Group A Streptococcal infection and potential vaccine implications: United States, 2000\u20132004","volume":"45","author":"O\u2019Loughlin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0460","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent Group A Streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0465","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of Group A Streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0470","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against Group A Streptococcus by immunization with J8-diptheria toxoid: contribution of J8- and diptheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0475","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymeth.2009.03.024","article-title":"A vaccine against S. pyogenes: design and experimental immune response","volume":"49","author":"Guilherme","year":"2009","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0480","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent Group A Streptococcal vaccine in healthy adults: phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2016.03.073_bib0485","first-page":"104","article-title":"Preclinical evaluation of a vaccine based on conserved region of M protein that prevents Group A Streptococcal infection","volume":"119","author":"Batzloff","year":"2004","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0490","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17402520600877026","article-title":"Towards a vaccine against rheumatic fever","volume":"13","author":"Guilherme","year":"2006","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0495","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/505146","article-title":"Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from Group A Streptococcus challenge and reduces throat colonization","volume":"194","author":"Batzloff","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0500","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.4049\/jimmunol.1500157","article-title":"A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia","volume":"194","author":"Pandey","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0505","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/JCM.00312-09","article-title":"emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development","volume":"47","author":"Steer","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0510","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/IAI.00295-10","article-title":"Novel conserved Group A Streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine","volume":"78","author":"Fritzer","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0515","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.015693","article-title":"Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case","volume":"11","author":"Bensi","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0520","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1016\/j.vaccine.2014.05.017","article-title":"Working towards a Group A Streptococcal vaccine: report of a collaborative Trans-Tasman workshop","volume":"32","author":"Moreland","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0525","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1440-1711.2002.01067.x","article-title":"Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical Group A Streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology","volume":"80","author":"Hayman","year":"2002","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0530","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4049\/jimmunol.145.4.1251","article-title":"Synthetic peptide vaccine against mucosal colonization by Group A Streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes","volume":"145","author":"Bessen","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0535","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/498618","article-title":"Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection","volume":"193","author":"Sabharwal","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0540","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical lancefield antigen of Group A Streptococcus is a virulence determinant with implications for vaccine design","volume":"15","author":"van Sorge","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0545","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.vaccine.2004.04.030","article-title":"Immunization with C5a peptidase from either group A or group B streptococci enhances clearance of Group A Streptococci from intranasally infected mice","volume":"22","author":"Cleary","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0550","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/IAI.69.2.924-930.2001","article-title":"Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice","volume":"69","author":"Kawabata","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0555","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1128\/IAI.72.12.7342-7345.2004","article-title":"Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model","volume":"72","author":"McArthur","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0560","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1128\/IAI.71.9.5097-5103.2003","article-title":"Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of Group A Streptococci","volume":"71","author":"Courtney","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0565","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1128\/IAI.68.9.5011-5017.2000","article-title":"Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome","volume":"68","author":"Roggiani","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0570","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/mpat.1994.1044","article-title":"Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous Group A Streptococci","volume":"16","author":"Kapur","year":"1994","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0575","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.165.4.2306","article-title":"Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome","volume":"165","author":"McCormick","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0580","doi-asserted-by":"crossref","first-page":"15641","DOI":"10.1073\/pnas.0507808102","article-title":"Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens","volume":"102","author":"Mora","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0585","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1128\/IAI.01706-14","article-title":"Structural conservation, variability, and immunogenicity of the T6 backbone pilin of serotype M6 Streptococcus pyogenes","volume":"82","author":"Young","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0590","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1016\/j.vaccine.2009.06.042","article-title":"Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi","volume":"27","author":"Turner","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0595","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.vaccine.2004.01.043","article-title":"Identification and assessment of new vaccine candidates for Group A Streptococcal infections","volume":"22","author":"McMillan","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.073_bib0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/380491","article-title":"Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins","volume":"189","author":"Lei","year":"2004","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:37:55Z","timestamp":1692272275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16300706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":60,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16300706"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of research and development of vaccines for Streptococcus pyogenes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}